Dr Luis Raez reviews three key genetic fusions in non-small cell lung cancer (NSCLC): NTRK, RET, and NRG1.

He begins with NTRK fusions, rare but highly actionable mutations found across multiple tumour types, highlighting the remarkable responses seen with TRK inhibitors like larotrectinib and entrectinib.

Next, he discusses RET rearrangements, found in about 1–2% of lung adenocarcinomas, emphasizing the effectiveness of selective RET inhibitors such as selpercatinib and pralsetinib.

Finally, Dr Raez addresses NRG1 fusions, an emerging and less understood aberration, often seen in invasive mucinous adenocarcinomas, where HER3-targeted therapies are showing early promise in clinical trials.

Dr Raez underscores the importance of comprehensive molecular profiling to detect these fusions and offer patients personalized and effective treatment options.